FALSE 0001673985 2023 Q2--12-31 0001673985 2023-01-01 2023-06-30 0001673985 2023-07-28 xbrli:shares 0001673985 2023-04-01 2023-06-30 iso4217:USD 0001673985 2022-04-01 2022-06-30 0001673985 2022-01-01 2022-06-30 iso4217:USD xbrli:shares 0001673985 2023-06-30 0001673985 2022-12-31 0001673985 2021-12-31 0001673985 2022-06-30 0001673985 us-gaap:CommonStockMember 2022-12-31 0001673985 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001673985 us-gaap:RetainedEarningsMember 2022-12-31 0001673985 us-gaap:TreasuryStockCommonMember 2022-12-31 0001673985 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001673985 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001673985 2023-01-01 2023-03-31 0001673985 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001673985 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001673985 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001673985 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001673985 us-gaap:CommonStockMember 2023-03-31 0001673985 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001673985 us-gaap:RetainedEarningsMember 2023-03-31 0001673985 us-gaap:TreasuryStockCommonMember 2023-03-31 0001673985 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001673985 2023-03-31 0001673985 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001673985 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001673985 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001673985 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001673985 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0001673985 us-gaap:CommonStockMember 2023-06-30 0001673985 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001673985 us-gaap:RetainedEarningsMember 2023-06-30 0001673985 us-gaap:TreasuryStockCommonMember 2023-06-30 0001673985 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001673985 us-gaap:CommonStockMember 2021-12-31 0001673985 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001673985 us-gaap:RetainedEarningsMember 2021-12-31 0001673985 us-gaap:TreasuryStockCommonMember 2021-12-31 0001673985 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001673985 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001673985 2022-01-01 2022-03-31 0001673985 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001673985 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001673985 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001673985 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0001673985 us-gaap:CommonStockMember 2022-03-31 0001673985 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001673985 us-gaap:RetainedEarningsMember 2022-03-31 0001673985 us-gaap:TreasuryStockCommonMember 2022-03-31 0001673985 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001673985 2022-03-31 0001673985 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001673985 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001673985 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001673985 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001673985 us-gaap:TreasuryStockCommonMember 2022-04-01 2022-06-30 0001673985 us-gaap:CommonStockMember 2022-06-30 0001673985 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001673985 us-gaap:RetainedEarningsMember 2022-06-30 0001673985 us-gaap:TreasuryStockCommonMember 2022-06-30 0001673985 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 asix:manufacuringSite 0001673985 asix:May2018RepurchaseProgramMember 2023-06-30 0001673985 asix:February2019RepurchaseProgramMember 2023-06-30 0001673985 asix:February2023RepurchaseProgramMember 2023-06-30 0001673985 2018-05-04 2023-06-30 0001673985 us-gaap:SubsequentEventMember 2023-07-01 2023-07-28 asix:customer asix:country 0001673985 us-gaap:CustomerConcentrationRiskMember asix:A10LargestCustomersMember us-gaap:RevenueFromContractWithCustomerMember 2023-04-01 2023-06-30 xbrli:pure 0001673985 us-gaap:CustomerConcentrationRiskMember asix:A10LargestCustomersMember us-gaap:RevenueFromContractWithCustomerMember 2022-04-01 2022-06-30 0001673985 us-gaap:CustomerConcentrationRiskMember asix:A10LargestCustomersMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-06-30 0001673985 us-gaap:CustomerConcentrationRiskMember asix:A10LargestCustomersMember us-gaap:RevenueFromContractWithCustomerMember 2023-01-01 2023-06-30 0001673985 asix:ShawIndustriesGroupIncMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2023-04-01 2023-06-30 0001673985 asix:ShawIndustriesGroupIncMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-06-30 0001673985 asix:ShawIndustriesGroupIncMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-04-01 2022-06-30 0001673985 asix:ShawIndustriesGroupIncMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2023-01-01 2023-06-30 0001673985 asix:NylonResinsMember 2023-04-01 2023-06-30 0001673985 asix:NylonResinsMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2023-04-01 2023-06-30 0001673985 asix:NylonResinsMember 2022-04-01 2022-06-30 0001673985 asix:NylonResinsMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-04-01 2022-06-30 0001673985 asix:NylonResinsMember 2023-01-01 2023-06-30 0001673985 asix:NylonResinsMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2023-01-01 2023-06-30 0001673985 asix:NylonResinsMember 2022-01-01 2022-06-30 0001673985 asix:NylonResinsMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-06-30 0001673985 asix:CaprolactamMember 2023-04-01 2023-06-30 0001673985 asix:CaprolactamMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2023-04-01 2023-06-30 0001673985 asix:CaprolactamMember 2022-04-01 2022-06-30 0001673985 asix:CaprolactamMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-04-01 2022-06-30 0001673985 asix:CaprolactamMember 2023-01-01 2023-06-30 0001673985 asix:CaprolactamMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2023-01-01 2023-06-30 0001673985 asix:CaprolactamMember 2022-01-01 2022-06-30 0001673985 asix:CaprolactamMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-06-30 0001673985 asix:ChemicalIntermediatesMember 2023-04-01 2023-06-30 0001673985 us-gaap:ProductConcentrationRiskMember asix:ChemicalIntermediatesMember us-gaap:RevenueFromContractWithCustomerMember 2023-04-01 2023-06-30 0001673985 asix:ChemicalIntermediatesMember 2022-04-01 2022-06-30 0001673985 us-gaap:ProductConcentrationRiskMember asix:ChemicalIntermediatesMember us-gaap:RevenueFromContractWithCustomerMember 2022-04-01 2022-06-30 0001673985 asix:ChemicalIntermediatesMember 2023-01-01 2023-06-30 0001673985 us-gaap:ProductConcentrationRiskMember asix:ChemicalIntermediatesMember us-gaap:RevenueFromContractWithCustomerMember 2023-01-01 2023-06-30 0001673985 asix:ChemicalIntermediatesMember 2022-01-01 2022-06-30 0001673985 us-gaap:ProductConcentrationRiskMember asix:ChemicalIntermediatesMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-06-30 0001673985 asix:AmmoniumSulfateFertilizersMember 2023-04-01 2023-06-30 0001673985 us-gaap:ProductConcentrationRiskMember asix:AmmoniumSulfateFertilizersMember us-gaap:RevenueFromContractWithCustomerMember 2023-04-01 2023-06-30 0001673985 asix:AmmoniumSulfateFertilizersMember 2022-04-01 2022-06-30 0001673985 us-gaap:ProductConcentrationRiskMember asix:AmmoniumSulfateFertilizersMember us-gaap:RevenueFromContractWithCustomerMember 2022-04-01 2022-06-30 0001673985 asix:AmmoniumSulfateFertilizersMember 2023-01-01 2023-06-30 0001673985 us-gaap:ProductConcentrationRiskMember asix:AmmoniumSulfateFertilizersMember us-gaap:RevenueFromContractWithCustomerMember 2023-01-01 2023-06-30 0001673985 asix:AmmoniumSulfateFertilizersMember 2022-01-01 2022-06-30 0001673985 us-gaap:ProductConcentrationRiskMember asix:AmmoniumSulfateFertilizersMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-06-30 0001673985 us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2023-04-01 2023-06-30 0001673985 us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-04-01 2022-06-30 0001673985 us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2023-01-01 2023-06-30 0001673985 us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-06-30 0001673985 country:US 2023-04-01 2023-06-30 0001673985 country:US us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2023-04-01 2023-06-30 0001673985 country:US 2022-04-01 2022-06-30 0001673985 country:US us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-04-01 2022-06-30 0001673985 country:US 2023-01-01 2023-06-30 0001673985 country:US us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2023-01-01 2023-06-30 0001673985 country:US 2022-01-01 2022-06-30 0001673985 country:US us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-06-30 0001673985 us-gaap:NonUsMember 2023-04-01 2023-06-30 0001673985 us-gaap:NonUsMember us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2023-04-01 2023-06-30 0001673985 us-gaap:NonUsMember 2022-04-01 2022-06-30 0001673985 us-gaap:NonUsMember us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-04-01 2022-06-30 0001673985 us-gaap:NonUsMember 2023-01-01 2023-06-30 0001673985 us-gaap:NonUsMember us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2023-01-01 2023-06-30 0001673985 us-gaap:NonUsMember 2022-01-01 2022-06-30 0001673985 us-gaap:NonUsMember us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-06-30 0001673985 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-04-01 2023-06-30 0001673985 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-04-01 2022-06-30 0001673985 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-06-30 0001673985 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-06-30 0001673985 srt:MaximumMember 2023-06-30 0001673985 asix:USAminesLtdMember us-gaap:CustomerRelationshipsMember srt:MinimumMember 2023-06-30 0001673985 asix:USAminesLtdMember us-gaap:CustomerRelationshipsMember srt:MaximumMember 2023-06-30 0001673985 asix:USAminesLtdMember us-gaap:TradeNamesMember 2023-06-30 0001673985 us-gaap:CustomerRelationshipsMember 2023-06-30 0001673985 us-gaap:CustomerRelationshipsMember 2022-12-31 0001673985 us-gaap:LicensingAgreementsMember 2023-06-30 0001673985 us-gaap:LicensingAgreementsMember 2022-12-31 0001673985 us-gaap:TradeNamesMember 2023-06-30 0001673985 us-gaap:TradeNamesMember 2022-12-31 asix:location 0001673985 2022-03-31 2022-03-31 0001673985 us-gaap:InterestRateSwapMember 2023-06-30 asix:derivative_instrument 0001673985 us-gaap:InterestRateSwapMember 2019-07-31 0001673985 us-gaap:InterestRateSwapMember 2018-11-30 0001673985 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0001673985 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001673985 us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0001673985 us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001673985 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0001673985 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-06-30 0001673985 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-06-30 0001673985 us-gaap:InterestRateContractMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001673985 us-gaap:InterestRateContractMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001673985 us-gaap:InterestRateContractMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001673985 us-gaap:InterestRateContractMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-06-30 0001673985 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001673985 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001673985 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001673985 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-06-30 0001673985 asix:USAminesLtdMember 2022-02-01 2022-02-28 0001673985 asix:CommonwealthIndustrialServicesIncMember 2021-01-01 2021-01-31 0001673985 us-gaap:SubsequentEventMember 2023-08-04 2023-08-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q

(Mark One)
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023
or

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____
Commission File Number: 1-37774

AdvanSix Inc.
(Exact name of registrant as specified in its charter)

Delaware |  | 81-2525089
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)

300 Kimball Drive, Suite 101, Parsippany, New Jersey |  | 07054
(Address of principal executive offices) |  | (Zip Code)

(973) 526-1800
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, par value $0.01 per share | ASIX | New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ý No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ý | Accelerated filer o | Non-accelerated filer o | Smaller reporting company ☐
|  |  | Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ý
The Registrant had 27,213,058 shares of common stock, $0.01 par value, outstanding at July 28, 2023.

ADVANSIX INC.
FORM 10-Q
TABLE OF CONTENTS

Part I. | FINANCIAL INFORMATION |
Item 1. | Financial Statements | 3
| Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2023 and 2022 (unaudited) | 3
| Condensed Consolidated Statements of Comprehensive Income for the three and six months ended June 30, 2023 and 2022 (unaudited) | 4
| Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022 (unaudited) | 5
| Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022 (unaudited) | 6
| Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2023 and 2022 (unaudited) | 7
| Notes to Condensed Consolidated Financial Statements (unaudited) | 9
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 18
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 28
Item 4. | Controls and Procedures | 28
Part II. | OTHER INFORMATION | 29
Item 1. | Legal Proceedings | 29
Item 1A. | Risk Factors | 29
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 29
Item 5. | Other Information | 30
Item 6. | Exhibits | 31
| Signature | 32

PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
ADVANSIX INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(Dollars in thousands, except share and per share amounts)

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Sales | $ | 427,940 |  |  | $ | 583,736 |  |  | $ | 828,484 |  |  | $ | 1,062,809 |
Costs, expenses and other: |  |  |  |  |  |  |
Costs of goods sold | 360,017 |  |  | 476,835 |  |  | 690,059 |  |  | 852,482 |
Selling, general and administrative expenses | 24,011 |  |  | 20,841 |  |  | 49,126 |  |  | 42,051 |
Interest expense, net | 1,954 |  |  | 769 |  |  | 3,221 |  |  | 1,332 |
Other non-operating (income) expense, net | (1,325) |  |  | 172 |  |  | (1,433) |  |  | (431) |
Total costs, expenses and other | 384,657 |  |  | 498,617 |  |  | 740,973 |  |  | 895,434 |
Income before taxes | 43,283 |  |  | 85,119 |  |  | 87,511 |  |  | 167,375 |
Income tax expense | 10,555 |  |  | 19,962 |  |  | 19,829 |  |  | 39,145 |
Net income | $ | 32,728 |  |  | $ | 65,157 |  |  | $ | 67,682 |  |  | $ | 128,230 |
Earnings per common share |  |  |  |  |  |  |
Basic | $ | 1.19 |  |  | $ | 2.31 |  |  | $ | 2.46 |  |  | $ | 4.55 |
Diluted | $ | 1.16 |  |  | $ | 2.23 |  |  | $ | 2.39 |  |  | $ | 4.37 |
Weighted average common shares outstanding |  |  |  |  |  |  |
Basic | 27,494,555 |  |  | 28,168,207 |  |  | 27,547,874 |  |  | 28,183,951 |
Diluted | 28,113,402 |  |  | 29,262,709 |  |  | 28,348,266 |  |  | 29,316,792 |

See accompanying notes to Condensed Consolidated Financial Statements.
3

ADVANSIX INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
(Dollars in thousands)

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Net income | $ | 32,728 |  |  | $ | 65,157 |  |  | $ | 67,682 |  |  | $ | 128,230 |
Foreign exchange translation adjustment | (125) |  |  | (35) |  |  | (158) |  |  | 22 |
Cash-flow hedges | — |  |  | 295 |  |  | (150) |  |  | 807 |
Other comprehensive income (loss), net of tax | (125) |  |  | 260 |  |  | (308) |  |  | 829 |
Comprehensive income | $ | 32,603 |  |  | $ | 65,417 |  |  | $ | 67,374 |  |  | $ | 129,059 |

See accompanying notes to Condensed Consolidated Financial Statements.
4

ADVANSIX INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(Dollars in thousands, except share and per share amounts)

| June 30, 2023 |  | December 31, 2022
ASSETS |  |  |
Current assets: |  |  |
Cash and cash equivalents | $ | 10,536 |  |  | $ | 30,985 |
Accounts and other receivables – net | 153,148 |  |  | 175,429 |
Inventories – net | 225,986 |  |  | 215,502 |
Taxes receivable | 1,442 |  |  | 9,771 |
Other current assets | 20,043 |  |  | 9,241 |
Total current assets | 411,155 |  |  | 440,928 |
Property, plant and equipment – net | 816,885 |  |  | 811,065 |
Operating lease right-of-use assets | 109,816 |  |  | 114,688 |
Goodwill | 56,192 |  |  | 56,192 |
Intangible assets | 47,717 |  |  | 49,242 |
Other assets | 25,244 |  |  | 23,216 |
Total assets | $ | 1,467,009 |  |  | $ | 1,495,331 |
LIABILITIES |  |  |
Current liabilities: |  |  |
Accounts payable | $ | 220,158 |  |  | $ | 272,770 |
Accrued liabilities | 43,310 |  |  | 48,820 |
Operating lease liabilities – short-term | 34,342 |  |  | 37,472 |
Deferred income and customer advances | 2,333 |  |  | 34,430 |
Total current liabilities | 300,143 |  |  | 393,492 |
Deferred income taxes | 164,256 |  |  | 160,409 |
Operating lease liabilities – long-term | 75,829 |  |  | 77,571 |
Line of credit – long-term | 140,000 |  |  | 115,000 |
Postretirement benefit obligations | 2,279 |  |  | — |
Other liabilities | 10,143 |  |  | 10,679 |
Total liabilities | 692,650 |  |  | 757,151 |
COMMITMENTS AND CONTINGENCIES (Note 9) |  |  |
STOCKHOLDERS' EQUITY |  |  |
Common stock, par value $0.01; 200,000,000 shares authorized; 32,577,862 shares issued and 27,302,873 outstanding at June 30, 2023; 31,977,593 shares issued and 27,446,520 outstanding at December 31, 2022 | 326 |  |  | 320 |
Preferred stock, par value $0.01; 50,000,000 shares authorized and 0 shares issued and outstanding at June 30, 2023 and December 31, 2022 | — |  |  | — |
Treasury stock at par (5,274,989 shares at June 30, 2023; 4,531,073 shares at December 31, 2022) | (53) |  |  | (45) |
Additional paid-in capital | 151,706 |  |  | 174,585 |
Retained earnings | 626,885 |  |  | 567,517 |
Accumulated other comprehensive loss | (4,505) |  |  | (4,197) |
Total stockholders' equity | 774,359 |  |  | 738,180 |
Total liabilities and stockholders' equity | $ | 1,467,009 |  |  | $ | 1,495,331 |

See accompanying notes to Condensed Consolidated Financial Statements.
5

ADVANSIX INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(Dollars in thousands)

| Six Months Ended June 30,
| 2023 |  | 2022
Cash flows from operating activities: |  |  |
Net income | $ | 67,682 |  |  | $ | 128,230 |
Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
Depreciation and amortization | 35,958 |  |  | 34,226 |
Loss on disposal of assets | 568 |  |  | 800 |
Deferred income taxes | 3,894 |  |  | 2,558 |
Stock-based compensation | 4,449 |  |  | 5,379 |
Amortization of deferred financing fees | 309 |  |  | 309 |
Changes in assets and liabilities, net of business acquisitions: |  |  |
Accounts and other receivables | 22,123 |  |  | (52,145) |
Inventories | (10,484) |  |  | 3,012 |
Taxes receivable | 8,329 |  |  | — |
Accounts payable | (47,216) |  |  | 52,439 |
Accrued liabilities | (5,744) |  |  | (8,821) |
Deferred income and customer advances | (32,097) |  |  | (1,142) |
Other assets and liabilities | (11,192) |  |  | (19,792) |
Net cash provided by operating activities | 36,579 |  |  | 145,053 |
Cash flows from investing activities: |  |  |
Expenditures for property, plant and equipment | (43,894) |  |  | (38,779) |
Acquisition of businesses | — |  |  | (97,456) |
Other investing activities | (2,034) |  |  | (1,221) |
Net cash used for investing activities | (45,928) |  |  | (137,456) |
Cash flows from financing activities: |  |  |
Borrowings from line of credit | 230,500 |  |  | 230,500 |
Payments of line of credit | (205,500) |  |  | (219,000) |
Principal payments of finance leases | (456) |  |  | (481) |
Dividend payments | (8,004) |  |  | (7,032) |
Purchase of treasury stock | (28,385) |  |  | (10,419) |
Issuance of common stock | 745 |  |  | 1,032 |
Net cash used for financing activities | (11,100) |  |  | (5,400) |
Net change in cash and cash equivalents | (20,449) |  |  | 2,197 |
Cash and cash equivalents at beginning of period | 30,985 |  |  | 15,100 |
Cash and cash equivalents at the end of period | $ | 10,536 |  |  | $ | 17,297 |
Supplemental non-cash investing activities: |  |  |
Capital expenditures included in accounts payable | $ | 9,832 |  |  | $ | 9,207 |
Supplemental cash activities: |  |  |
Cash paid for interest | $ | 3,027 |  |  | $ | 1,024 |
Cash paid for income taxes | $ | 7,024 |  |  | $ | 47,439 |

See accompanying notes to Condensed Consolidated Financial Statements.
6

ADVANSIX INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(Unaudited)
(Dollars in thousands)

| Common Stock |  | Additional Paid-In Capital |  | Retained Earnings |  |  |  | Treasury Stock |  | Accumulated Other Comprehensive Income (Loss) |  | Total Equity
Shares |  | Amount |
Balance at December 31, 2022 | 31,977,593 |  |  | $ | 320 |  |  | $ | 174,585 |  |  | $ | 567,517 |  |  |  |  | $ | (45) |  |  | $ | (4,197) |  |  | $ | 738,180 |
Net Income | — |  |  | — |  |  | — |  |  | 34,954 |  |  |  |  | — |  |  | — |  |  | 34,954 |
Comprehensive income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign exchange translation adjustments | — |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | (33) |  |  | (33) |
Cash-flow hedges | — |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | (150) |  |  | (150) |
Other comprehensive income (loss), net of tax | — |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | (183) |  |  | (183) |
Issuance of common stock | 555,249 |  |  | 5 |  |  | 617 |  |  | — |  |  |  |  | — |  |  | — |  |  | 622 |
Purchase of treasury stock (333,054 shares) | — |  |  | — |  |  | (13,496) |  |  | — |  |  |  |  | (3) |  |  | — |  |  | (13,499) |
Stock-based compensation | — |  |  | — |  |  | 2,013 |  |  | — |  |  |  |  | — |  |  | — |  |  | 2,013 |
Dividends | — |  |  | — |  |  | 112 |  |  | (4,132) |  |  |  |  | — |  |  | — |  |  | (4,020) |
Balance at March 31, 2023 | 32,532,842 |  |  | 325 |  |  | 163,831 |  |  | 598,339 |  |  |  |  | (48) |  |  | (4,380) |  |  | 758,067 |
Net Income | — |  |  | — |  |  | — |  |  | 32,728 |  |  |  |  | — |  |  | — |  |  | 32,728 |
Comprehensive income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign exchange translation adjustments | — |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | (125) |  |  | (125) |
Cash-flow hedges | — |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | — |  |  | — |
Other comprehensive income (loss), net of tax | — |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | (125) |  |  | (125) |
Issuance of common stock | 45,020 |  |  | 1 |  |  | 122 |  |  | — |  |  |  |  | — |  |  | — |  |  | 123 |
Purchase of treasury stock (410,862 shares) | — |  |  | — |  |  | (14,881) |  |  | — |  |  |  |  | (5) |  |  | — |  |  | (14,886) |
Stock-based compensation | — |  |  | — |  |  | 2,436 |  |  | — |  |  |  |  | — |  |  | — |  |  | 2,436 |
Dividends | — |  |  | — |  |  | 198 |  |  | (4,182) |  |  |  |  | — |  |  | — |  |  | (3,984) |
Balance at June 30, 2023 | 32,577,862 |  |  | $ | 326 |  |  | $ | 151,706 |  |  | $ | 626,885 |  |  |  |  | $ | (53) |  |  | $ | (4,505) |  |  | $ | 774,359 |

7

ADVANSIX INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(Unaudited)
(Dollars in thousands)

| Common Stock |  | Additional Paid-In Capital |  | Retained Earnings |  |  |  | Treasury Stock |  | Accumulated Other Comprehensive Income (Loss) |  | Total Equity
Shares |  | Amount |
Balance at December 31, 2021 | 31,755,430 |  |  | $ | 318 |  |  | $ | 195,931 |  |  | $ | 411,516 |  |  |  |  | $ | (36) |  |  | $ | (6,539) |  |  | $ | 601,190 |
Net Income | — |  |  | — |  |  | — |  |  | 63,073 |  |  |  |  | — |  |  | — |  |  | 63,073 |
Comprehensive income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign exchange translation adjustments | — |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 57 |  |  | 57 |
Cash-flow hedges | — |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 512 |  |  | 512 |
Other comprehensive income (loss), net of tax | — |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 569 |  |  | 569 |
Issuance of common stock | 144,875 |  |  | 1 |  |  | 713 |  |  | — |  |  |  |  | — |  |  | — |  |  | 714 |
Purchase of treasury stock (181,536 shares) | — |  |  | — |  |  | (7,010) |  |  | — |  |  |  |  | (2) |  |  | — |  |  | (7,012) |
Stock-based compensation | — |  |  | — |  |  | 3,374 |  |  | — |  |  |  |  | — |  |  | — |  |  | 3,374 |
Dividends | — |  |  | — |  |  | 313 |  |  | (3,830) |  |  |  |  | — |  |  | — |  |  | (3,517) |
Balance at March 31, 2022 | 31,900,305 |  |  | 319 |  |  | 193,321 |  |  | 470,759 |  |  |  |  | (38) |  |  | (5,970) |  |  | 658,391 |
Net Income | — |  |  | — |  |  | — |  |  | 65,157 |  |  |  |  | — |  |  | — |  |  | 65,157 |
Comprehensive income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign exchange translation adjustments | — |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | (35) |  |  | (35) |
Cash-flow hedges | — |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 295 |  |  | 295 |
Other comprehensive income (loss), net of tax | — |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 260 |  |  | 260 |
Issuance of common stock | 61,651 |  |  | 1 |  |  | 317 |  |  | — |  |  |  |  | — |  |  | — |  |  | 318 |
Purchase of treasury stock (87,251 shares) | — |  |  | — |  |  | (3,406) |  |  | — |  |  |  |  | (1) |  |  | — |  |  | (3,407) |
Stock-based compensation | — |  |  | — |  |  | 2,005 |  |  | — |  |  |  |  | — |  |  | — |  |  | 2,005 |
Dividends | — |  |  | — |  |  | 155 |  |  | (3,670) |  |  |  |  | — |  |  | — |  |  | (3,515) |
Balance at June 30, 2022 | 31,961,956 |  |  | $ | 320 |  |  | $ | 192,392 |  |  | $ | 532,246 |  |  |  |  | $ | (39) |  |  | $ | (5,710) |  |  | $ | 719,209 |

See accompanying notes to Condensed Consolidated Financial Statements.
8

ADVANSIX INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in thousands, except share and per share amounts and as otherwise noted)
1. Organization, Operations and Basis of Presentation
Description of Business
AdvanSix Inc. ("AdvanSix," the "Company," "we" or "our") is a diversified chemistry company playing a critical role in global supply chains, innovating and delivering essential products for our customers in a wide variety of end markets and applications that touch people’s lives, such as building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics. Our reliable and sustainable supply of quality products emerges from the integrated value chain of our five U.S.-based manufacturing facilities. AdvanSix strives to deliver best-in-class customer experiences and differentiated products in the industries of nylon solutions, chemical intermediates and plant nutrients, guided by our core values of Safety, Integrity, Accountability and Respect.
Basis of Presentation
The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company's financial position as of June 30, 2023, and its results of operations for the three and six months ended June 30, 2023 and 2022 and cash flows for the six months ended June 30, 2023 and 2022. The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the full fiscal year. These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the "2022 Form 10-K"). All intercompany transactions have been eliminated.
Certain prior period amounts have been reclassified for consistency with the current period presentation.
It is our practice to establish actual quarterly closing dates using a predetermined fiscal calendar, which requires our businesses to close their books on a Saturday in order to minimize the potentially disruptive effects of quarterly closing on our business processes. Historically, the effects of this practice have generally not been significant to reported results for any quarter and only existed within a reporting year. In the event that differences in actual closing dates are material to year-over-year comparisons of quarterly or year-to-date results, we will provide the appropriate disclosures. Our actual closing dates for the three and six months ended June 30, 2023 and 2022 were July 1, 2023 and July 2, 2022, respectively.
Liabilities to creditors to whom we have issued checks that remained outstanding at June 30, 2023 and December 31, 2022 aggregated to $3.7 million and $9.0 million, respectively, and were included in Cash and cash equivalents and Accounts payable in the Condensed Consolidated Balance Sheets.
The Company's Board of Directors (the "Board") has authorized share repurchase programs to repurchase shares of the Company's common stock as follows:

Date of Authorization |  | Authorized Amount (millions) |  |  |  |  |  | Authorized Amount Remaining as of June 30, 2023 (millions)
May 4, 2018 |  | $ | 75.0 |  |  |  |  |  |  | $ | — |
February 22, 2019 |  | 75.0 |  |  |  |  |  |  | 10.6 |
February 17, 2023 |  | 75.0 |  |  |  |  |  |  | 75.0 |
Totals |  | $ | 225.0 |  |  |  |  |  |  | $ | 85.6 |

Repurchases may be made from time to time on the open market in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including through the use of trading plans intended to qualify under Rule
9

ADVANSIX INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in thousands, except share and per share amounts and as otherwise noted)
10b5-1 of the Exchange Act. The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The share repurchase program has no expiration date and may be modified, suspended or discontinued at any time. The par value of the shares repurchased is applied to Treasury stock and the excess of the purchase price over par value is applied to Additional paid-in capital.
As of June 30, 2023, the Company has repurchased a total of 5,274,989 shares of common stock, including 849,265 shares withheld to cover tax withholding obligations in connection with the vesting of awards, for an aggregate of $164.4 million at a weighted average market price of $31.17 per share. As of June 30, 2023, $85.6 million remained available for share repurchases under the current authorization. During the period July 1, 2023 through July 28, 2023, the Company repurchased an additional 94,715 shares at a weighted average market price of $36.45 per share primarily under the current authorized repurchase program.
2. Recent Accounting Pronouncements
Recent Accounting Pronouncements – The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial position or results of operations.
In September 2022, the FASB issued ASU No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations. The amendments in this ASU require that a buyer in a supplier finance program disclose sufficient quantitative and qualitative information about its supplier finance programs to allow a user of the financial statements to understand the program’s nature, activity during the period, changes from period to period and potential magnitude. On a retrospective basis, for each annual reporting period, an entity should disclose the key terms of the program, including a description of the payment terms, assets pledged as security or other forms of guarantees, the confirmed amount outstanding that remains unpaid, a description of where the obligations are presented in the balance sheet and a roll-forward of those obligations confirmed as well as the amount of obligations subsequently paid. In each interim reporting period, an entity should disclose the amount of confirmed obligations outstanding. The guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on roll-forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption of the amendments in this update is permitted. The Company adopted ASU 2022-04, effective January 1, 2023, which did not have a material impact on the Company's consolidated financial position or results of operations upon adoption.
3. Revenues
Revenue Recognition
We serve approximately 400 customers annually in approximately 40 countries across a wide variety of industries. For the three months ended June 30, 2023 and 2022, the Company's ten largest customers accounted for approximately 41% and 40% of total sales, respectively. For each of the six months ended June 30, 2023 and 2022, the Company's ten largest customers accounted for approximately 38% of total sales during both periods.
We typically sell to customers under master service agreements, with primarily one-year terms, or by purchase orders. We have historically experienced low customer turnover and have long-standing customer relationships, which span decades. Our largest customer is Shaw Industries Group, Inc. (“Shaw”), a significant consumer of caprolactam and Nylon 6 resin, to whom we sell under a long-term agreement. For each of the three and six months ended June 30, 2023 and 2022, the Company's sales to Shaw were 10% of our total sales.
The Company's revenue by product line, and related approximate percentage of total sales, for the three and six months ended June 30, 2023 and 2022 were as follows:
10

ADVANSIX INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in thousands, except share and per share amounts and as otherwise noted)

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Nylon | $ | 92,953 |  |  | 22% |  | $ | 132,105 |  |  | 23% |  | $ | 192,325 |  |  | 23% |  | $ | 250,715 |  |  | 23%
Caprolactam | 74,682 |  |  | 18% |  | 87,169 |  |  | 15% |  | 147,073 |  |  | 18% |  | 157,174 |  |  | 15%
Chemical Intermediates | 121,365 |  |  | 28% |  | 158,611 |  |  | 27% |  | 235,929 |  |  | 28% |  | 294,300 |  |  | 28%
Ammonium Sulfate | 138,940 |  |  | 32% |  | 205,851 |  |  | 35% |  | 253,157 |  |  | 31% |  | 360,620 |  |  | 34%
Total | $ | 427,940 |  |  | 100% |  | $ | 583,736 |  |  | 100% |  | $ | 828,484 |  |  | 100% |  | $ | 1,062,809 |  |  | 100%

The Company's revenues by geographic area, and related approximate percentage of total sales, for the three and six months ended June 30, 2023 and 2022 were as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
United States | $ | 367,608 |  |  | 86% |  | $ | 494,155 |  |  | 85% |  | $ | 688,534 |  |  | 83 | % |  | $ | 897,174 |  |  | 84 | %
International | 60,332 |  |  | 14% |  | 89,581 |  |  | 15% |  | 139,950 |  |  | 17 | % |  | 165,635 |  |  | 16 | %
Total | $ | 427,940 |  |  | 100% |  | $ | 583,736 |  |  | 100% |  | $ | 828,484 |  |  | 100 | % |  | $ | 1,062,809 |  |  | 100 | %

Deferred Income and Customer Advances
The Company defers revenues when cash payments are received in advance of our performance. Below is a roll-forward of Deferred income and customer advances for the six months ended June 30, 2023:

Opening balance January 1, 2023 | $ | 34,430 |
Additional cash advances | 5,878 |
Less amounts recognized in revenues | (37,975) |
Ending balance June 30, 2023 | $ | 2,333 |

The Company expects to recognize as revenue the June 30, 2023 ending balance of Deferred income and customer advances within one year or less.
4. Earnings Per Share
The computation of basic and diluted earnings per share ("EPS") is based on Net income divided by the basic weighted average number of common shares outstanding and diluted weighted average number of common shares outstanding, respectively. The details of the basic and diluted EPS calculations for the three and six months ended June 30, 2023 and 2022 were as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Basic |  |  |  |  |  |  |
Net income | $ | 32,728 |  |  | $ | 65,157 |  |  | $ | 67,682 |  |  | $ | 128,230 |
Weighted average common shares outstanding | 27,494,555 |  |  | 28,168,207 |  |  | 27,547,874 |  |  | 28,183,951 |
EPS – Basic | $ | 1.19 |  |  | $ | 2.31 |  |  | $ | 2.46 |  |  | $ | 4.55 |
Diluted |  |  |  |  |  |  |
Dilutive effect of equity awards and other stock-based holdings | 618,847 |  |  | 1,094,502 |  |  | 800,392 |  |  | 1,132,841 |
Weighted average common shares outstanding | 28,113,402 |  |  | 29,262,709 |  |  | 28,348,266 |  |  | 29,316,792 |
EPS – Diluted | $ | 1.16 |  |  | $ | 2.23 |  |  | $ | 2.39 |  |  | $ | 4.37 |

11

ADVANSIX INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in thousands, except share and per share amounts and as otherwise noted)
Diluted EPS is computed based upon the weighted average number of common shares outstanding for the period plus the dilutive effect of common stock equivalents using the treasury stock method and the average market price of our common stock for the period.
The diluted EPS calculations exclude the effect of stock options when the options’ assumed proceeds exceed the average market price of the common shares during the period. The anti-dilutive common stock equivalents outstanding at the three and six months ended June 30, 2023 and 2022 were as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Options and stock equivalents | 503,354 |  |  | 121,794 |  |  | 404,009 |  |  | 121,055 |

Dividend activity for the three and six months ended June 30, 2023 and 2022 was as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Cash dividends declared per share | $ | 0.145 |  |  | $ | 0.125 |  |  | $ | 0.290 |  |  | $ | 0.250 |
Aggregate dividends paid to shareholders | $ | 3,984 |  |  | $ | 3,515 |  |  | $ | 8,004 |  |  | $ | 7,032 |

5. Accounts and Other Receivables – Net

| June 30, 2023 |  | December 31, 2022
Accounts receivables | $ | 149,303 |  |  | $ | 171,923 |
Other | 5,106 |  |  | 4,100 |
Total accounts and other receivables | 154,409 |  |  | 176,023 |
Less – allowance for doubtful accounts | (1,261) |  |  | (594) |
Total accounts and other receivables – net | $ | 153,148 |  |  | $ | 175,429 |

6. Inventories

| June 30, 2023 |  | December 31, 2022
Raw materials | $ | 125,162 |  |  | $ | 126,060 |
Work in progress | 73,417 |  |  | 64,669 |
Finished goods | 92,824 |  |  | 60,711 |
Spares and other | 30,894 |  |  | 28,892 |
| 322,297 |  |  | 280,332 |
Reduction to LIFO cost basis | (96,311) |  |  | (64,830) |
Total inventories | $ | 225,986 |  |  | $ | 215,502 |

Substantially all of the Company’s inventories at June 30, 2023 and December 31, 2022 are valued at the lower of cost or market using the last-in, first-out (“LIFO”) method. However, approximately 7% was valued at average cost using the first-in, first-out (“FIFO”) method at June 30, 2023.
The excess of replacement cost over the carrying value of total inventories subject to LIFO was $67.2 million and $58.2 million at June 30, 2023 and December 31, 2022, respectively.
7. Leases
We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use assets ("ROU"), Operating lease liabilities – short-term, and Operating lease liabilities – long-term in our Condensed Consolidated Balance Sheets. Finance leases are included in Property, plant and equipment – net, Accounts payable, and Other liabilities in our Condensed Consolidated Balance Sheets.
12

ADVANSIX INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in thousands, except share and per share amounts and as otherwise noted)
The components of lease expense were as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Finance lease cost: |  |  |  |  |  |  |
Amortization of right-of-use asset | $ | 216 |  |  | $ | 238 |  |  | $ | 438 |  |  | $ | 474 |
Interest on lease liabilities | 23 |  |  | 8 |  |  | 41 |  |  | 22 |
Total finance lease cost | 239 |  |  | 246 |  |  | 479 |  |  | 496 |
Operating lease cost | 11,592 |  |  | 10,272 |  |  | 22,841 |  |  | 20,610 |
Short-term lease cost | 1,511 |  |  | 1,244 |  |  | 2,537 |  |  | 2,598 |
Total lease cost | $ | 13,342 |  |  | $ | 11,762 |  |  | $ | 25,857 |  |  | $ | 23,704 |

As of June 30, 2023, we have additional operating leases that have not yet commenced for approximately $1.0 million. These leases will commence during the second half of 2023 with lease terms of up to 7 years.
8. Goodwill and Intangible Assets
Intangible assets with finite lives acquired through a business combination are recorded at fair value, less accumulated amortization. Customer relationships and trade-names are amortized on a straight-line basis over their expected useful lives of 15 to 20 years and 5 years, respectively.
Goodwill
There was no change in the carrying amount of goodwill for the six months ended June 30, 2023.
Finite-Lived Intangible Assets
Intangible assets subject to amortization were as follows:

| June 30, 2023 |  | December 31, 2022 |  |
| Gross Carrying Amount |  | Accumulated Amortization |  | Net Book Value |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Book Value |  |  |  |
Customer relationships | $ | 36,820 |  |  | $ | (2,807) |  |  | $ | 34,013 |  |  | $ | 36,820 |  |  | $ | (1,854) |  |  | $ | 34,966 |  |  |  |  |
Licenses | 18,451 |  |  | (5,535) |  |  | 12,916 |  |  | 18,451 |  |  | (5,074) |  |  | 13,377 |  |  |  |  |
Trade names | 1,100 |  |  | (312) |  |  | 788 |  |  | 1,100 |  |  | (201) |  |  | 899 |  |  |  |  |
Total | $ | 56,371 |  |  | $ | (8,654) |  |  | $ | 47,717 |  |  | $ | 56,371 |  |  | $ | (7,129) |  |  | $ | 49,242 |  |  |  |  |

For each of the three months ended June 30, 2023 and June 30, 2022, the Company recorded amortization expense on intangible assets of $0.8 million. For the six months ended June 30, 2023 and June 30, 2022, the Company recorded amortization expense on intangible assets of $1.5 million and $1.2 million, respectively.
9. Commitments and Contingencies
The Company is subject to a number of lawsuits, investigations and disputes, some of which may involve substantial amounts claimed, arising out of the conduct of the Company or other third-parties in the normal and ordinary course of business. A liability is recognized for any contingency that is probable of occurrence and reasonably estimable. The Company continually assesses the likelihood of adverse judgments or outcomes in these matters, as well as potential ranges of possible losses, based on an analysis of each matter with the assistance of legal counsel and, if applicable, other experts.
Given the uncertainty inherent in such lawsuits, investigations and disputes, the Company does not believe it is possible to develop estimates of reasonably possible loss in excess of current accruals for these matters. Considering the Company’s past experience and existing accruals, the Company does not expect the outcome of these matters, either individually or in the
13

ADVANSIX INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in thousands, except share and per share amounts and as otherwise noted)
aggregate, to have a material adverse effect on the Company’s consolidated financial position or results of operations. Potential liabilities are subject to change due to new developments, changes in settlement strategy or the impact of evidentiary requirements, which could cause the Company to pay damage awards or settlements (or become subject to equitable remedies) that could have a material adverse effect on the Company’s consolidated results of operations, balance sheet and/or operating cash flows in the periods recognized or paid.
We assumed from Honeywell International Inc. ("Honeywell") all health, safety and environmental (“HSE”) liabilities and compliance obligations related to the past and future operations of our current business as of the spin-off, as well as all HSE liabilities associated with the three manufacturing locations assumed from Honeywell that are used in our current operations, including any cleanup or other liabilities related to any contamination that may have occurred at such locations in the past. Honeywell retained all HSE liabilities related to former business locations or the operation of our former businesses. Although we have ongoing environmental remedial obligations at certain of our facilities, in the past three years, the associated remediation costs have not been material, and we do not expect our known remediation costs to have a material adverse effect on the Company's consolidated financial position or results of operations.
10. Income Taxes
The provision for income taxes was $10.6 million and $20.0 million for the three months ended June 30, 2023 and 2022, respectively, resulting in an effective tax rate of 24.4% and 23.5%, respectively. The provision for income taxes was $19.8 million and $39.1 million for the six months ended June 30, 2023 and 2022, respectively, resulting in an effective tax rate of 22.7% and 23.4%, respectively.
The Company’s provision for income taxes in interim periods is computed by applying an estimated annual effective tax rate against Income before taxes for the period in addition to recording any tax effects of discrete items for the quarter. The Company’s effective tax rate for the three and six months ended June 30, 2023 and 2022 differed from the U.S. federal statutory rate, due to the impacts of state taxes and executive compensation deduction limitations which generally increase the tax rate, offset by tax credits and the foreign-derived intangible income deduction which generally decrease the tax rate. Additionally, discrete tax adjustments recorded in the first half of 2023 relating to the vesting of equity compensation and changes in state tax legislation resulted in a net 0.6% increase to the quarterly effective tax rate and a net 0.9% decrease to the year-to-date effective tax rate.
On August 16, 2022, the Inflation Reduction Act of 2022 (the "IRA") was signed into law. This legislation includes significant changes relating to tax, climate change, energy and health care. Among other provisions, the IRA introduces a corporate alternative minimum tax (CAMT) on adjusted financial statement income of certain large corporations and a 1% excise tax on share repurchases. The Company is not currently subject to the CAMT which became effective for tax years beginning after December 31, 2022. The 1% excise tax is generally applicable to publicly traded corporations for the net value of certain stock that the corporation repurchases during the year and is also effective for tax years beginning after December 31, 2022. The impact of any excise tax imposed on the Company for share repurchases is generally accounted for as an equity transaction with no consequences to the Company's results in operations, and this provision of the law is not expected to have a material impact on the Company's financial condition. The IRA also includes significant extensions, expansions and enhancements related to climate and energy tax credits designed to encourage investment in the adoption and expansion of renewable and alternative energy sources. The Company continues to evaluate these energy credit provisions of the law in relation to our sustainability and environmental, social and governance initiatives.
11. Fair Value Measurements
Financial and non-financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. In July 2019, the Company entered into an interest rate swap transaction related to its credit agreement. The interest rate swap, considered a Level 2 liability, expired February 21, 2023.
The pension plan assets are invested in collective investment trust funds. These investments are measured at fair value using the net asset value per share as a practical expedient. Investments valued using the net asset value method (NAV) (or its equivalent) practical expedient are excluded from the fair value hierarchy disclosure.
The Company’s Condensed Consolidated Balance Sheets also include Cash and cash equivalents, Accounts receivable and Accounts payable all of which are recorded at amounts which approximate fair value.
14

ADVANSIX INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in thousands, except share and per share amounts and as otherwise noted)
The Company also has assets that are required to be recorded at fair value on a non-recurring basis. These assets are evaluated when certain triggering events occur (including a decrease in estimated future cash flows) that indicate the asset should be evaluated for impairment which could result in such assets being measured at fair value. Goodwill must be evaluated at least annually. Our annual evaluation occurred on March 31, 2023 and we concluded that an impairment for goodwill did not occur.
12. Derivative and Hedging Instruments
The specific credit and market, commodity price and interest rate risks to which the Company is exposed in connection with its ongoing business operations are described below. This discussion includes an explanation of any hedging instrument and interest rate swap agreement, used to manage the Company’s interest rate risk associated with a fixed and floating-rate borrowing.
For cash flow hedges, the entire change in the fair value of the hedging instrument included in the assessment of hedge effectiveness is recorded in Other comprehensive income. Those amounts are reclassified to earnings in the same income statement line item that is used to present the earnings effect of the hedged item when the hedged item affects earnings.
Credit and Market Risk – Financial instruments, including derivatives, expose the Company to counterparty credit risk for non-performance and to market risk related to changes in commodity prices, interest rates and foreign currency exchange rates. The Company manages its exposure to counterparty credit risk through specific minimum credit standards, diversification of counterparties, and procedures to monitor concentrations of credit risk. The Company’s counterparties in derivative transactions are substantial investment and commercial banks with significant experience using such derivative instruments. The Company monitors the impact of market risk on the fair value and cash flows of its derivative and other financial instruments considering reasonably possible changes in commodity prices, interest rates and foreign currency exchange rates and restricts the use of derivative financial instruments to hedging activities.
The Company continually monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. The terms and conditions of credit sales are designed to mitigate or eliminate concentrations of credit risk with any single customer. The Company did not have any customers with significant concentrations of trade accounts receivable – net at June 30, 2023 or December 31, 2022. Allowance for doubtful accounts is calculated based upon the Company's estimate of expected credit losses over the life of exposure based upon both historical information as well as future expected losses.
Commodity Price Risk Management – The Company's exposure to market risk for commodity prices can result in changes in the cost of production. We primarily mitigate our exposure to commodity price risk by using long-term, formula-based price contracts with our suppliers and formula-based price agreements with customers. Our customer agreements provide for price adjustments based on relevant market indices and raw material prices and generally do not include take-or-pay terms. We may also enter into forward commodity contracts with third-parties designated as hedges of anticipated purchases of several commodities. Forward commodity contracts are marked-to-market, with the resulting gains and losses recognized in earnings, in the same category as the items being hedged, when the hedged transaction is recognized. At June 30, 2023 and 2022, we had no financial contracts related to forward commodity agreements.
Interest Rate Risk Management – The Company had entered into one interest rate swap agreement for a total notional amount of $50 million to exchange floating for fixed rate interest payments for our LIBOR-based borrowings. The interest rate swap had a fair value of zero at inception and was effective July 31, 2019 and matured on February 21, 2023. In accordance with ASC 815, the Company designated the interest rate swap as a cash flow hedge of floating-rate borrowings. The interest rate swap converted the Company’s interest rate payments on the first $50 million of variable-rate, 1-month LIBOR-based debt to a fixed interest rate. The interest rate swap involved the receipt of floating rate amounts in exchange for fixed rate interest payments over the life of the interest rate swap without an exchange of the underlying principal amount.
15

ADVANSIX INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in thousands, except share and per share amounts and as otherwise noted)

| Asset (Liability) Derivatives |  |  |
| June 30, 2023 |  | December 31, 2022 |  |  |  |  |
| Balance Sheet Classification | Fair Value |  | Balance Sheet Classification | Fair Value |  |  |  |  |  |
Derivatives designated as hedging instruments under ASC 815: |  |  |  |  |
Interest Rate Contracts | Accounts and other receivables, net | $ | — |  |  | Accounts and other receivables, net | $ | 197 |  |  |  |  |  |  |
Total Derivatives |  | $ | — |  |  |  | $ | 197 |  |  |  |  |  |  |

The following table summarizes adjustments related to cash flow hedge included in Cash-flow hedges, in the Condensed Consolidated Statements of Comprehensive Income:

|  |  |  | June 30, 2023
Gain on derivative instruments included in Accumulated other comprehensive loss at December 31, 2022 | $ | 197 |
Fair value adjustment | (197) |
Gain (Loss) on derivative instruments included in Accumulated other comprehensive loss at June 30, 2023 | $ | — |

At June 30, 2023, the Company expects no reclassifications of net gains or losses on derivative instruments from Accumulated other comprehensive income ("AOCI") to earnings during the next 12 months as the interest rate swap agreement matured on February 21, 2023. The following table summarizes the reclassification of net (gains) losses on derivative instruments from AOCI into earnings:

| Amount of (Gain) Loss Recognized in Earnings
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Derivatives: |  |  |  |  |  |
Interest Rate Contracts | $ | — |  |  | $ | (131) |  |  | $ | — |  |  | $ | (119) |
Total Derivatives | $ | — |  |  | $ | (131) |  |  | $ | — |  |  | $ | (119) |

13. Acquisitions
In February 2022, the Company acquired the stock of U.S. Amines, a leading North American producer of alkyl and specialty amines serving high-value end markets such as agrochemicals and pharmaceuticals for a purchase price of approximately $97.5 million, net of cash acquired.
In January 2021, the Company acquired certain assets associated with ammonium sulfate packaging, warehousing and logistics services in Virginia from Commonwealth Industrial Services, Inc. ("CIS") for approximately $9.5 million.
14. Supplier Finance Programs
The Company has entered into a supply chain finance program with a financial intermediary providing participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. AdvanSix’s responsibility is limited to making payments to the intermediary based upon payment terms negotiated with the suppliers, regardless of whether the intermediary pays the supplier in advance of the original due date. The Company’s payment terms with suppliers are consistent, regardless of whether a vendor participates in the supply chain finance program or not. All related agreements are terminable by either party upon at least 30 days’ notice.
The total amount due to the financial intermediaries to settle supplier invoices under the supplier finance programs was approximately $14 million and approximately $17 million as of June 30, 2023 and December 31, 2022, respectively. These amounts outstanding are included in Accounts payable.
16

ADVANSIX INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in thousands, except share and per share amounts and as otherwise noted)
15. Subsequent Events
As announced on August 4, 2023, the Board declared a quarterly cash dividend of $0.160 per share on the Company's common stock, payable on August 29, 2023 to stockholders of record as of the close of business on August 15, 2023.
17

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of the Company’s financial condition and results of operations, which we refer to as our “MD&A,” should be read in conjunction with the Condensed Consolidated Financial Statements and the notes thereto contained in this Quarterly Report on Form 10-Q (this "Form 10-Q"), as well as the MD&A section included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (“SEC”) on February 17, 2023 (the “2022 Form 10-K”). Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Actual results and the timing of events may differ materially from those contained in these forward-looking statements due to a number of factors that can affect our performance in both the near- and long-term, including those incorporated by reference in Item 1A of Part II of this Form 10-Q as such factors may be revised or supplemented in subsequent filings with the SEC, as well as those discussed in the section entitled “Note Regarding Forward-Looking Statements” below.
Note Regarding Forward-Looking Statements
All statements other than statements of historical fact included in this Form 10-Q including, without limitation, statements in this MD&A regarding our financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). When used in this Form 10-Q, words such as "expect," “anticipate,” "estimate," "outlook," "project," "strategy," "intend," "plan," "target," "goal," "may," "will," "should," and “believe,” and other variations or similar terminology and expressions identify forward-looking statements. Although we believe forward-looking statements are based upon reasonable assumptions, such statements involve known and unknown risks, uncertainties and other factors, many of which are beyond our control and difficult to predict, which may cause the actual results or performance of the Company to be materially different from any future results or performance expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: general economic and financial conditions in the U.S. and globally, including the impact of the coronavirus (COVID-19) pandemic and any resurgences; the potential effects of inflationary pressures, labor market shortages and supply chain issues; instability or volatility in financial markets or other unfavorable economic or business conditions caused by geopolitical concerns, including as a result of the conflict between Russia and Ukraine; the effect on our customers’ demand for our products and our suppliers’ ability to manufacture and deliver our raw materials, including implications of reduced refinery utilization in the U.S.; our ability to sell and provide our goods and services; the ability of our customers to pay for our products; any closures of our and our customers’ offices and facilities; risks associated with increased phishing, compromised business emails and other cybersecurity attacks and disruptions to our technology infrastructure; risks associated with employees working remotely or operating with a reduced workforce; risks associated with our indebtedness including compliance with financial and restrictive covenants, and our ability to access capital on reasonable terms, at a reasonable cost, or at all, due to economic conditions or otherwise; the impact of scheduled turnarounds and significant unplanned downtime and interruptions of production or logistics operations as a result of mechanical issues or other unanticipated events such as fires, severe weather conditions, natural disasters, pandemics, geopolitical conflicts and related events; price fluctuations, cost increases and supply of raw materials; our operations and growth projects requiring substantial capital; growth rates and cyclicality of the industries we serve including global changes in supply and demand; failure to develop and commercialize new products or technologies; loss of significant customer relationships; adverse trade and tax policies; extensive environmental, health and safety laws that apply to our operations; hazards associated with chemical manufacturing, storage and transportation; litigation associated with chemical manufacturing and our business operations generally; inability to acquire and integrate businesses, assets, products or technologies; protection of our intellectual property and proprietary information; prolonged work stoppages as a result of labor difficulties or otherwise; cybersecurity, data privacy incidents and disruptions to our technology infrastructure; failure to maintain effective internal controls; our ability to declare and pay quarterly cash dividends and the amounts and timing of any future dividends; our ability to repurchase our common stock and the amount and timing of any future repurchases; disruptions in supply chain, transportation and logistics; potential for uncertainty regarding qualification for tax treatment of our spin-off; fluctuations in our stock price; and changes in laws or regulations applicable to our business. Forward-looking statements are not guarantees of future performance and actual results could differ materially from those contemplated by the forward-looking statements as a result of a number of risks, uncertainties and other factors including those noted above and those detailed in Item 1A of Part I and elsewhere in our 2022 Form 10-K, and subsequent reports filed with the SEC. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. We do not undertake to update or revise any of our forward-looking statements.
Business Overview
18

AdvanSix is a diversified chemistry company playing a critical role in global supply chains, innovating and delivering essential products for our customers in a wide variety of end markets and applications that touch people’s lives, such as building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics. Our reliable and sustainable supply of quality products emerges from the integrated value chain of our five U.S.-based manufacturing facilities. AdvanSix strives to deliver best-in-class customer experiences and differentiated products in the industries of nylon solutions, chemical intermediates and plant nutrients, guided by our core values of Safety, Integrity, Accountability and Respect. Our four key product lines are as follows:
•Nylon – We sell our Nylon 6 resin globally, primarily under the Aegis® brand name. Nylon 6 is a polymer resin which is a synthetic material used by our customers to produce fibers, filaments, engineered plastics and films that, in turn, are used in such end-products as carpets, automotive and electric components, sports apparel, food packaging and other industrial applications. In addition, our Nylon 6 resin is used to produce nylon films which we sell to our customers primarily under the Capran® brand name.
•Caprolactam – Caprolactam is the key monomer used in the production of Nylon 6 resin. We internally polymerize caprolactam into Aegis® Nylon 6 Resins, and we also market and sell the caprolactam that is not consumed internally to customers who use it to manufacture polymer resins to produce nylon fibers, films and other nylon products. Our Hopewell, VA manufacturing facility is one of the world’s largest single-site producers of caprolactam as of June 30, 2023.
•Chemical Intermediates – We manufacture, market and sell a number of other chemical intermediate products that are derived from the manufacturing processes within our integrated supply chain. Most significant is acetone which is used by our customers in the production of adhesives, paints, coatings, solvents, herbicides and engineered plastic resins. Other intermediate chemicals that we manufacture, market and sell include phenol, alpha-methylstyrene (“AMS”), cyclohexanone, oximes (methyl ethyl ketoxime, acetaldehyde oxime and 2-pentanone oxime), cyclohexanol, sulfuric acid, ammonia and carbon dioxide. With the acquisition of U.S. Amines Limited (“U.S. Amines”), we now produce alkyl and specialty amines serving high-value end markets such as agrochemicals and pharmaceuticals.
•Ammonium Sulfate – Our ammonium sulfate is used by customers as a fertilizer containing nitrogen and sulfur, two key plant nutrients. Ammonium sulfate fertilizer is derived from the integrated operations at the Hopewell manufacturing facility. Because of our Hopewell facility’s size, scale and technology design, we are the world’s largest single-site producer of ammonium sulfate fertilizer as of June 30, 2023. We market and sell ammonium sulfate primarily to North American and South American distributors, farm cooperatives and retailers to fertilize crops.
Global demand for Nylon 6 resin spans a variety of end-uses such as textiles, engineered plastics, industrial filament, food and industrial films, and carpet. The market growth typically tracks global GDP growth over the long-term but varies by end-use. Generally, prices for Nylon 6 resin and caprolactam reflect supply and demand trends in the marketplace as well as the value of the basic raw materials used in the production of caprolactam, consisting primarily of benzene and, depending on the manufacturing process utilized, natural gas and sulfur. The global prices for nylon resin typically track a spread over the price of caprolactam, which in turn tracks as a spread over benzene because the key feedstock materials for caprolactam, phenol or cyclohexane, are derived from benzene. This price spread has historically experienced variation as a result of global changes in supply and demand. Nylon 6 resin prices generally track caprolactam prices, although prices set above the average commodity spread are achievable when nylon resin manufacturers, like AdvanSix, formulate and produce differentiated nylon resin products for current and new customer applications. Our differentiated Nylon 6 products, such as our wire and cable and co-polymer offerings, are typically valued at a higher level than commodity resin products.
We also manufacture, market and sell a number of chemical intermediate products that are derived from the manufacturing processes within our integrated supply chain. Most significant is acetone, the price of which is influenced by its own supply and demand dynamics but can also be influenced by the underlying move in propylene input costs. Our differentiated product offerings include high-purity applications and high-value intermediates including our U.S. Amines portfolio as well as our oximes-based EZ-Blox™ anti-skinning agent used in paints and Nadone® cyclohexanone, which is a solvent used in various high-value applications.
Global prices for ammonium sulfate fertilizer are influenced by several factors including the price of urea, which is the most widely used source of nitrogen-based fertilizer in the world. Other global factors driving ammonium sulfate fertilizer demand are general agriculture trends, including planted acres and the price of crops. Our ammonium sulfate product is positioned with the added value proposition of sulfur nutrition to increase yields of key crops. In addition, due to its nutrient density, the typical ammonium sulfate product delivers pound for pound the most readily available sulfur and nitrogen to crops as compared to other fertilizers. We also directly supply packaged ammonium sulfate to customers, primarily in North and South America, and
19

diversified and optimized our offerings to include spray-grade adjuvants to support crop protection, as well as other specialty fertilizers and products for industrial use.
We produce ammonium sulfate fertilizer continuously throughout the year as part of our manufacturing process, however, quarterly sales experience seasonality reflecting both geographical and product sales mix considerations based on the timing and length of the growing seasons in North and South America. The North America planting season runs from July through June. The new season fill typically occurs in the third quarter and proceeds sequentially into the following spring which is the peak period for fertilizer application for key crops in North America. As a result of this typical pattern, North American ammonium sulfate demand and pricing, particularly for our higher-value granular product, are typically the strongest in the first half of the year through application for the spring crop and then decline in the second half. Our export sales, primarily into South America, are predominantly of the standard grade product. Due to the ammonium sulfate fertilizer sales cycle, we occasionally build up higher inventory balances because our production is continuous and not tied to seasonal demand for fertilizers. Sales of most of our other products have generally been subject to minimal, or no, seasonality.
We seek to run our production facilities on a nearly continuous basis for maximum efficiency as several of our intermediate products are key feedstock materials for other products in our integrated manufacturing chain. While our integration, scale and range of product offerings make us one of the most efficient manufacturers in our industry, these attributes also expose us to increased risk associated with material disruptions at any one of our production facilities or logistics operations which could impact the overall manufacturing supply chain. Further, although we believe that our sources of supply for our raw materials, including cumene, natural gas and sulfur, are generally robust, it is difficult to predict the impact that shortages, increased costs and related supply chain logistics considerations may have in the future. In order to mitigate the risk of unplanned interruptions, we schedule planned plant turnarounds each year to conduct routine and major maintenance across our facilities. We also utilize maintenance excellence and mechanical integrity programs, targeted buffer inventory of intermediate chemicals necessary for our manufacturing process, and co-producer swap arrangements, which are intended to mitigate the extent of any production losses as a result of planned and unplanned downtime; however, the mitigation of all or part of any such production impact cannot be assured.
Recent Developments
Share Repurchase Authorization
On February 17, 2023, the Company announced that the Board authorized a share repurchase program of up to an additional $75 million of the Company's common stock, which was in addition to the remaining capacity available under the previously approved share repurchase program. Repurchases may be made from time to time on the open market in accordance with Rule 10b-18 of the Exchange Act, including through the use of trading plans intended to qualify under Rule 10b5-1 of the Exchange Act. The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The repurchase program has no expiration date and may be modified, suspended or discontinued at any time.
Hopewell South Collective Bargaining Agreement
On April 7, 2023, the Company issued a press release announcing that a labor strike had been initiated by the Hopewell South bargaining unit, consisting of the International Chemical Workers Union Council/the United Food and Commercial Workers, Local 591-C, the International Brotherhood of Electrical Workers, Local 666, the International Association of Machinists and Aerospace Workers, Local No. 10, and the United Association of Journeymen and Apprentices of the Plumbing and Pipe Fitting Industry, Local 851, affecting approximately 340 workers at the Company's manufacturing facility in Hopewell, Virginia. The Company had robust contingency measures in place and was well prepared to support safe, stable and sustainable operations during this period. On May 8, 2023, the Company announced that the Hopewell South bargaining unit voted to ratify a new five-year collective bargaining agreement and that Hopewell South employees would return to work on May 10, 2023. The strike did not have a material impact on the Company's results of operations.
Dividends
During 2023, the Company has declared dividends as follows:
20

Date of Announcement |  | Date of Record |  | Date Payable |  | Dividend per Share |  |
8/4/2023 |  | 8/15/2023 |  | 8/29/2023 |  | $0.160 |  |  |
5/5/2023 |  | 5/16/2023 |  | 5/30/2023 |  | $0.145 |  |  |
2/17/2023 |  | 3/3/2023 |  | 3/17/2023 |  | $0.145 |  |  |

Results of Operations
(Dollars in thousands, unless otherwise noted)
Sales

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Sales | $ | 427,940 |  |  | $ | 583,736 |  |  | $ | 828,484 |  |  | $ | 1,062,809 |
% change compared with prior year period | (26.7)% |  |  |  | (22.0)% |  |

The change in sales compared to the prior year period is attributable to the following:

| Three Months Ended June 30, 2023 |  | Six Months Ended June 30, 2023
Volume | (1.5)% |  | (4.6)%
Price | (25.2)% |  | (18.5)%
Acquisition | —% |  | 1.1%
| (26.7)% |  | (22.0)%

Sales decreased in the three months ended June 30, 2023 compared to the prior year period by $155.8 million (approximately 27%) due to (i) net unfavorable market-based pricing (approximately 19%) primarily reflecting lower pricing across our ammonium sulfate and nylon product lines, (ii) lower raw material pass-through pricing (approximately 6%) as a result of a net cost decrease in benzene and propylene (inputs to cumene which is a key feedstock to our products) and (iii) a decrease in sales volume (approximately 2%).
Sales decreased in the six months ended June 30, 2023 compared to the prior year period by $234.3 million (approximately 22%) due to (i) net unfavorable market-based pricing (approximately 13%) primarily reflecting lower pricing across our ammonium sulfate and nylon product lines, (ii) unfavorable raw material pass-through pricing (approximately 6%) as a result of a net cost decrease in benzene and propylene (inputs to cumene which is a key feedstock to our products) and (iii) decreased sales volume (approximately 5%) largely driven by chemical intermediates, partially offset by the acquisition of U.S. Amines (approximately 1%).
Costs of Goods Sold

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Costs of goods sold | $ | 360,017 |  |  | $ | 476,835 |  |  | $ | 690,059 |  |  | $ | 852,482 |
% change compared with prior year period | (24.5)% |  |  |  | (19.1)% |  |
Gross Margin percentage | 15.9% |  | 18.3% |  | 16.7% |  | 19.8%

Costs of goods sold decreased in the three months ended June 30, 2023 compared to the prior year period by $116.8 million (approximately 24%) due to (i) decreased prices of raw materials (approximately 22%) and (ii) decrease in sales volume (approximately 2%).
Costs of goods sold decreased in the six months ended June 30, 2023 compared to the prior year period by $162.4 million (approximately 19%) due to (i) decreased prices of raw materials (approximately 17%) and (ii) lower sales volume (approximately 4%), partially offset by increased plant costs (approximately 2%) and the impact of the U.S. Amines acquisition (approximately 1%).
21

Gross margin percentage decreased in the three months ended June 30, 2023 compared to the prior year period (approximately 2%) due primarily to the impact of market-based pricing, net of raw material costs (approximately 4%) partially offset by (i) the net impact of lower sales volume and changes in sales mix, including higher domestic plant nutrients' sales (approximately 1%) and (ii) lower planned plant turnaround expenses (approximately 1%).
Gross margin percentage decreased in the six months ended June 30, 2023 compared to the prior year period (approximately 3%) due primarily to (i) increased plant spend (approximately 2%) and (ii) the impact of market-based pricing, net of raw material costs (approximately 1%).
Selling, General and Administrative Expenses

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Selling, general and administrative expenses | $ | 24,011 |  |  | $ | 20,841 |  |  | $ | 49,126 |  |  | $ | 42,051 |
Percentage of Sales | 5.6% |  | 3.6% |  | 5.9% |  | 4.0%

Selling, general and administrative expenses increased by $3.2 million in the three months ended June 30, 2023 compared to the prior year period due primarily to upgrades to our enterprise resource planning systems and other functional support costs, and a reduction in bad debt expense in the prior year period associated with a cash collection of a previously reserved customer receivable.
Selling, general and administrative expenses increased by $7.1 million in the six months ended June 30, 2023 compared to the prior year period due primarily to increased functional support costs including upgrades to our enterprise resource planning system, and a reduction in bad debt expense in the prior year period associated with a cash collection of a previously reserved customer receivable partially offset by lower incentive-based compensation costs.
Income Tax Expense

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Income tax expense | $ | 10,555 |  |  | $ | 19,962 |  |  | $ | 19,829 |  |  | $ | 39,145 |
Effective tax rate | 24.4% |  | 23.5% |  | 22.7% |  | 23.4%

The Company’s effective tax rate for the three and six months ended June 30, 2023 and 2022 differed from the U.S. federal statutory rate, due to the impacts of state taxes and executive compensation deduction limitations which generally increase the tax rate, offset by tax credits and the foreign-derived intangible income deduction which generally decrease the tax rate. Additionally, discrete tax adjustments recorded in the first half of 2023 relating to the vesting of equity compensation and changes in state tax legislation resulted in a net 0.6% increase to the quarterly effective tax rate and a net 0.9% decrease to the year-to-date effective tax rate.
The Company's effective tax rate for the three months ended June 30, 2023 was higher than the prior year period due primarily to state tax legislation changes enacted in the current period that resulted in a 0.7% increase to the Company's quarterly effective tax rate. The Company's effective tax rate for the six months ended June 30, 2023 was lower than the prior year period due primarily to the vesting of equity compensation that resulted in a 1.3% decrease to the Company's effective tax rate in the current year.
On August 16, 2022, the Inflation Reduction Act of 2022 (the "IRA") was signed into law. This legislation includes significant changes relating to tax, climate change, energy and health care. Among other provisions, the IRA introduces a corporate alternative minimum tax (CAMT) on adjusted financial statement income of certain large corporations and a 1% excise tax on share repurchases. The Company is not currently subject to the CAMT which became effective for tax years beginning after December 31, 2022. The 1% excise tax is generally applicable to publicly traded corporations for the net value of certain stock that the corporation repurchases during the year and is also effective for tax years beginning after December 31, 2022. The impact of any excise tax imposed on the Company for share repurchases is generally accounted for as an equity transaction with no consequences to the Company's results in operations, and this provision of the law is not expected to have a material impact on the Company's financial condition. The IRA also includes significant extensions, expansions and enhancements related to
22

climate and energy tax credits designed to encourage investment in the adoption and expansion of renewable and alternative energy sources. The Company continues to evaluate these energy credit provisions of the law in relation to our sustainability and environmental, social and governance initiatives.
Net Income

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Net income | $ | 32,728 |  |  | $ | 65,157 |  |  | $ | 67,682 |  |  | $ | 128,230 |

As a result of the factors described above, Net income was $32.7 million and $67.7 million for the three and six months ended June 30, 2023 as compared to $65.2 million and $128.2 million in the corresponding prior year period.
Non-GAAP Measures
(Dollars in thousands, unless otherwise noted)
The following tables set forth the non-GAAP financial measures of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income and Adjusted Earnings Per Share. Adjusted EBITDA is defined as Net income before Interest, Income taxes, Depreciation and amortization, Non-cash stock-based compensation, Non-recurring, unusual or extraordinary expenses, Non-cash amortization from acquisitions and One-time merger and acquisition costs. Adjusted EBITDA Margin is equal to Adjusted EBITDA divided by Sales. The Company believes these non-GAAP financial measures provide meaningful supplemental information as they are used by the Company’s management to evaluate the Company’s operating performance, enhance a reader’s understanding of the financial performance of the Company, and facilitate a better comparison among fiscal periods and performance relative to its competitors, as the non-GAAP measures exclude items that management believes do not reflect the Company’s ongoing operations.
These non-GAAP results are presented for supplemental informational purposes only and should not be considered a substitute for the financial information presented in accordance with U.S. GAAP. Non-GAAP financial measures should be read only in conjunction with the comparable U.S. GAAP financial measures. The Company's non-GAAP measures may not be comparable to other companies' non-GAAP measures.
The following is a reconciliation between the non-GAAP financial measures of Adjusted Net Income, Adjusted EBITDA and Adjusted EBITDA Margin to their most directly comparable U.S. GAAP financial measure:

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Net income | $ | 32,728 |  |  | $ | 65,157 |  |  | $ | 67,682 |  |  | $ | 128,230 |
Non-cash stock-based compensation | 2,436 |  |  | 2,005 |  |  | 4,449 |  |  | 5,379 |
Non-cash amortization from acquisitions | 532 |  |  | 551 |  |  | 1,064 |  |  | 752 |
Non-recurring M&A costs | — |  |  | — |  |  | — |  |  | 277 |
Benefit from income taxes relating to reconciling items | (498) |  |  | (439) |  |  | (933) |  |  | (995) |
Adjusted Net Income (non-GAAP) | 35,198 |  |  | 67,274 |  |  | 72,262 |  |  | 133,643 |
Interest expense, net | 1,954 |  |  | 769 |  |  | 3,221 |  |  | 1,332 |
Income tax expense - adjusted | 11,053 |  |  | 20,401 |  |  | 20,763 |  |  | 40,141 |
Depreciation and amortization - adjusted | 17,580 |  |  | 16,982 |  |  | 34,893 |  |  | 33,474 |
Adjusted EBITDA (non-GAAP) | $ | 65,785 |  |  | $ | 105,426 |  |  | 131,139 |  |  | 208,590 |
Sales | $ | 427,940 |  |  | $ | 583,736 |  |  | $ | 828,484 |  |  | $ | 1,062,809 |
Adjusted EBITDA Margin * (non-GAAP) | 15.4% |  | 18.1% |  | 15.8% |  | 19.6%

* Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Sales
23

The following is a reconciliation between the non-GAAP financial measures of Adjusted Earnings Per Share to its most directly comparable U.S. GAAP financial measure:

|  | Three Months Ended June 30, |  | Six Months Ended June 30,
|  | 2023 |  | 2022 |  | 2023 |  | 2022
Net Income |  | $ | 32,728 |  |  | $ | 65,157 |  |  | $ | 67,682 |  |  | $ | 128,230 |
Adjusted Net Income (non-GAAP) |  | 35,198 |  |  | 67,274 |  |  | 72,262 |  |  | 133,643 |
Weighted-average number of common shares outstanding - basic |  | 27,494,555 |  |  | 28,168,207 |  |  | 27,547,874 |  |  | 28,183,951 |
Dilutive effect of equity awards and other stock-based holdings |  | 618,847 |  |  | 1,094,502 |  |  | 800,392 |  |  | 1,132,841 |
Weighted-average number of common shares outstanding - diluted |  | 28,113,402 |  |  | 29,262,709 |  |  | 28,348,266 |  |  | 29,316,792 |
EPS - Basic |  | $ | 1.19 |  |  | $ | 2.31 |  |  | $ | 2.46 |  |  | $ | 4.55 |
EPS - Diluted |  | $ | 1.16 |  |  | $ | 2.23 |  |  | $ | 2.39 |  |  | $ | 4.37 |
Adjusted EPS - Basic (non-GAAP) |  | $ | 1.28 |  |  | $ | 2.39 |  |  | $ | 2.62 |  |  | $ | 4.74 |
Adjusted EPS - Diluted (non-GAAP) |  | $ | 1.25 |  |  | $ | 2.30 |  |  | $ | 2.55 |  |  | $ | 4.56 |

Liquidity and Capital Resources
(Dollars in thousands, unless otherwise noted)
Liquidity
We believe that cash balances and operating cash flows, together with available capacity under our credit agreement, will provide adequate funds to support our current short-term operating objectives as well as our longer-term strategic plans, subject to the risks and uncertainties outlined below, in our "Note Regarding Forward-Looking Statements" above, and in the risk factors previously disclosed in Item 1A of Part I of our 2022 Form 10-K. Our principal source of liquidity is our cash flow generated from operating activities, which is expected to provide us with the ability to meet the majority of our short-term funding requirements. Our cash flows are affected by capital requirements and production volume, which may be materially impacted by unanticipated events such as unplanned downtime, material disruptions at our production facilities, the prices of our raw materials, general economic and industry trends and customer demand. The Company applies a proactive and disciplined approach to working capital management to optimize cash flow and to enable capital allocation options in support of the Company’s strategy. We utilize supply chain financing and trade receivables discount arrangements with third-party financial institutions which optimize terms and conditions related to accounts receivable and accounts payable in order to enhance liquidity and enable us to efficiently manage our working capital needs. Although we continue to optimize supply chain financing and trade receivable programs in the ordinary course, our utilization of these arrangements has not had a material impact on our liquidity. In addition, we monitor the third-party depository institutions that hold our cash and cash equivalents. Our emphasis is primarily on the safety of principal and secondarily on maximizing yield on those funds. We diversify our cash and cash equivalents among counterparties to minimize exposure to any one of these entities.
On a recurring basis, our primary future cash needs will be centered on operating activities, working capital, capital expenditures, dividends and liquidity reflecting disciplined capital deployment. Capital expenditures are deployed for various ongoing investments and initiatives to improve reliability, yield and quality, expand production capacity and comply with health, safety and environmental ("HSE") regulations. We believe that our future cash from operations, together with cash on hand and our access to credit and capital markets, will provide adequate resources to fund our expected operating and financing needs and obligations. Our ability to fund our capital needs, however, will depend on our ongoing ability to generate cash from operations and access to credit and capital markets, both of which are subject to the risk factors previously disclosed in Item 1A of Part I of our 2022 Form 10-K, as well as general economic, financial, competitive, regulatory and other factors that are beyond our control.
24

As of the end of the second quarter of 2023, the Company had approximately $10.5 million of cash on hand with approximately $359 million of additional capacity available under the revolving credit facility. The Company’s Consolidated Leverage Ratio financial covenant of its credit facility allows it to net up to $75 million of cash with debt. Capital expenditures are expected to be approximately $110 million to $120 million in 2023 compared to $89 million in 2022, reflecting increased spend due to critical infrastructure, other maintenance, and growth and cost savings projects.
We assumed from Honeywell International Inc. ("Honeywell") all HSE liabilities and compliance obligations related to the past and future operations of our current business as of the spin-off, as well as all HSE liabilities associated with the three manufacturing locations assumed from Honeywell that are used in our current operations, including any cleanup or other liabilities related to any contamination that may have occurred at such locations in the past. Honeywell retained all HSE liabilities related to former business locations or the operation of our former businesses. Although we have ongoing environmental remedial obligations at certain of our facilities, in the past three years, the associated remediation costs have not been material, and we do not expect our known remediation costs to have a material adverse effect on the Company's consolidated financial position or results of operations.
We expect that our primary cash requirements for 2023 will be to fund costs associated with ongoing operations, capital expenditures, and amounts related to other contractual obligations.
The Company made no cash contributions to the defined benefit pension plan during the six months ended June 30, 2023. The Company expects cash contributions of up to $5 million in 2023 and additional contributions in future years sufficient to satisfy pension funding requirements in those periods.
The Company's Board of Directors (the "Board") has authorized share repurchase programs to repurchase shares of the Company's common stock as follows:

Date of Authorization |  | Authorized Amount (millions) |  |  |  |  |  | Authorized Amount Remaining as of June 30, 2023 (millions)
May 4, 2018 |  | $ | 75.0 |  |  |  |  |  |  | $ | — |
February 22, 2019 |  | 75.0 |  |  |  |  |  |  | 10.6 |
February 17, 2023 |  | 75.0 |  |  |  |  |  |  | 75.0 |
Totals |  | $ | 225.0 |  |  |  |  |  |  | $ | 85.6 |

Repurchases may be made from time to time on the open market in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including through the use of trading plans intended to qualify under Rule 10b5-1 of the Exchange Act. The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The share repurchase program has no expiration date and may be modified, suspended or discontinued at any time. The par value of the shares repurchased is applied to Treasury stock and the excess of the purchase price over par value is applied to Additional paid-in capital.
As of June 30, 2023, the Company has repurchased a total of 5,274,989 shares of common stock life-to-date, including 849,265 shares withheld to cover tax withholding obligations in connection with the vesting of awards, for an aggregate of $164.4 million at a weighted average market price of $31.17 per share. As of June 30, 2023, $85.6 million remained available for share repurchases under the current authorization. During the period from July 1, 2023 through July 28, 2023, we repurchased an additional 94,715 shares at a weighted average market price of $36.45 per share primarily under the currently authorized repurchase program.
As of June 30, 2023, the Company did not have any off-balance sheet arrangements as described in Instruction 8 to Item 303(b) of Regulation S-K and did not have any material changes in the commitments or contractual obligations detailed in the Company's 2022 Form 10-K (see Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" under "Liquidity and Capital Resources - Liquidity"). The Company has not guaranteed any debt or commitments of other entities or entered into any options on non-financial assets.
Dividends
The Company commenced the declaration of dividends on September 28, 2021.
25

Since commencement of dividends, the Company has declared dividends as follows:

Date of Announcement |  | Date of Record |  | Date Payable |  | Dividend per Share |  | Total Approximate Dividend Amount ($M)
8/4/2023 |  | 8/15/2023 |  | 8/29/2023 |  | $0.160 |  | $ | 4.4 |  |  |  |
5/5/2023 |  | 5/16/2023 |  | 5/30/2023 |  | $0.145 |  | $ | 4.0 |  |  |  |
2/17/2023 |  | 3/3/2023 |  | 3/17/2023 |  | $0.145 |  | $ | 4.0 |  |  |  |
11/4/2022 |  | 11/15/2022 |  | 11/29/2022 |  | $0.145 |  | $ | 4.0 |  |  |  |
8/5/2022 |  | 8/16/2022 |  | 8/30/2022 |  | $0.145 |  | $ | 4.1 |  |  |  |
5/6/2022 |  | 5/17/2022 |  | 5/31/2022 |  | $0.125 |  | $ | 3.5 |  |  |  |
2/18/2022 |  | 3/1/2022 |  | 3/15/2022 |  | $0.125 |  | $ | 3.5 |  |  |  |
9/28/2021 |  | 11/9/2021 |  | 11/23/2021 |  | $0.125 |  | $ | 3.5 |  |  |  |

The timing, declaration, amount and payment of future dividends to stockholders, if any, will fall within the discretion of our Board. Holders of shares of our common stock will be entitled to receive dividends when, and if, declared by our Board at its discretion out of funds legally available for that purpose, subject to the terms of our indebtedness, the preferential rights of any preferred stock that may be outstanding, legal requirements, regulatory constraints, industry practice and other factors that our Board deems relevant.
Credit Agreement
On September 30, 2016, the Company as the borrower, entered into a Credit Agreement with Bank of America, as administrative agent (the "Original Credit Agreement"), which was amended on February 21, 2018 pursuant to Amendment No. 1 to the Original Credit Agreement (the "First Amended and Restated Credit Agreement"), and further amended on February 19, 2020 pursuant to, Amendment No. 2 to the First Amended and Restated Credit Agreement (after giving effect to the Second Amendment, the “Second Amended and Restated Credit Agreement”). The Second Amended and Restated Credit Agreement had a five-year term with a scheduled maturity date of February 21, 2023.
On October 27, 2021, the Company completed a refinancing of the Second Amended and Restated Credit Agreement by entering into a new Credit Agreement (the “Credit Agreement”), among the Company, the lenders party thereto, the swing line lenders party thereto, the letter of credit issuers party thereto and Truist Bank, as administrative agent, which provides for a new senior secured revolving credit facility in an aggregate principal amount of $500 million (the “Revolving Credit Facility”).
Borrowings under the Revolving Credit Facility are subject to customary borrowing conditions.
The Revolving Credit Facility has a scheduled maturity date of October 27, 2026. The Credit Agreement permits the Company to utilize up to $40 million of the Revolving Credit Facility for the issuance of letters of credit and up to $40 million for swing line loans. The Company has the option to establish a new class of term loans and/or increase the amount of the Revolving Credit Facility in an aggregate principal amount for all such incremental term loans and increases of the Revolving Credit Facility of up to the sum of (x) $175 million plus (y) an amount such that the Company’s Consolidated First Lien Secured Leverage Ratio (as defined in the Credit Agreement) would not be greater than 2.75 to 1.00, in each case, to the extent that any one or more lenders, whether or not currently party to the Credit Agreement, commits to be a lender for such amount or any portion thereof.
With the cessation of LIBOR on June 30, 2023 and subject to the First Amendment to the Credit Agreement, dated as of June 27, 2023, the Eurodollar Rate was replaced with the Adjusted Term SOFR as an alternative benchmark rate for purposes of the Credit Agreement. The transition was effective July 1, 2023. Borrowings under the Credit Agreement bear interest at a rate equal to either the sum of a base rate plus a margin ranging from 0.25% to 1.25% or the sum of an Adjusted Term SOFR rate plus a margin ranging from 1.25% to 2.25%, with either such margin varying according to the Company’s Consolidated Leverage Ratio (as defined in the Credit Agreement). The Company is also required to pay a commitment fee in respect of unused commitments under the Revolving Credit Facility, if any, at a rate ranging from 0.15% to 0.35% per annum depending on the Company’s Consolidated Leverage Ratio. As of June 30, 2023, the applicable margin under the Credit Agreement was 0.25% for base rate loans and 1.25% for Adjusted Term SOFR loans and the applicable commitment fee rate was 0.15% per annum.
26

Substantially all tangible and intangible assets of the Company and its domestic subsidiaries are pledged as collateral to secure the obligations under the Credit Agreement.
The Credit Agreement contains customary covenants limiting the ability of the Company and its subsidiaries to, among other things, pay cash dividends, incur debt or liens, redeem or repurchase stock of the Company, enter into transactions with affiliates, make investments, make capital expenditures, merge or consolidate with others or dispose of assets. The Credit Agreement also contains financial covenants that require the Company to maintain a Consolidated Interest Coverage Ratio (as defined in the Credit Agreement) of not less than 3.00 to 1.00 and to maintain a Consolidated Leverage Ratio of (i) 4.00 to 1.00 or less for the fiscal quarter ending December 31, 2021, through and including the fiscal quarter ending September 30, 2023 and (ii) 3.75 to 1.00 or less for each fiscal quarter thereafter (subject to the Company’s option to elect a consolidated leverage ratio increase in connection with certain acquisitions). If the Company does not comply with the covenants in the Credit Agreement, the lenders may, subject to customary cure rights, require the immediate payment of all amounts outstanding under the Revolving Credit Facility. We were in compliance with all of our covenants at June 30, 2023 and through the date of the filing of this Form 10-Q.
We had a borrowed balance of $115 million under the Revolving Credit Facility at December 31, 2022. We borrowed an incremental net amount of $25 million during the six months ended June 30, 2023, bringing the balance under the Revolving Credit Facility to $140 million, and available credit for use of approximately $359 million as of June 30, 2023. We expect that Cash provided by operating activities will fund future interest payments on the Company's outstanding indebtedness.
Cash Flow Summary

| Six Months Ended June 30,
| 2023 |  | 2022
Cash provided by (used for): |  |  |
Operating activities | $ | 36,579 |  |  | $ | 145,053 |
Investing activities | (45,928) |  |  | (137,456) |
Financing activities | (11,100) |  |  | (5,400) |
Net change in cash and cash equivalents | $ | (20,449) |  |  | $ | 2,197 |

Cash provided by operating activities decreased by $108.5 million for the six months ended June 30, 2023 versus the prior year period due primarily to (i) a $69.8 million unfavorable cash impact from working capital (comprised of Accounts and other receivables, Inventories, Accounts payable and Deferred income and customer advances) year-over-year largely driven by changes occurring during the six months ended June 30, 2023 and (ii) a $60.5 million decrease in net income. This was partially offset by (i) an $8.6 million favorable cash impact from Other assets and liabilities driven primarily by a reduction in the net pension liability due to previous year cash contributions to the defined benefit pension plan, (ii) an $8.3 million favorable cash impact from Taxes receivable and (iii) a $3.1 million favorable cash impact from accrued liabilities primarily due to lower short-term incentive payments during the six months ended June 30, 2023 compared to the prior year period.
Cash used for investing activities decreased by $91.5 million for the six months ended June 30, 2023 versus the prior year period due primarily to cash paid for the acquisition of U.S. Amines for approximately $97.5 million during the prior year period, and increased cash payments for capital expenditures of approximately $5.1 million during the current year period due primarily to increased spend for critical infrastructure, other maintenance, and growth and cost savings projects.
Cash used for financing activities increased by $5.7 million for the six months ended June 30, 2023 versus the prior year period due primarily to payments for share repurchases of $28.4 million and cash paid for dividends of approximately $8.0 million during the six months ended June 30, 2023 compared to $10.4 million and $7.0 million during the prior year period, respectively, partially offset by net borrowings of $25.0 million during the six months ended June 30, 2023 compared to net borrowings of $11.5 million during the prior year period.
Capital Expenditures
(Dollars in thousands, unless otherwise noted)
Our operations are capital intensive, requiring ongoing investments that have consisted, and are expected to continue to consist, primarily of capital expenditures required to maintain and improve equipment reliability, expand production output, further improve mix, yield and cost position, and comply with environmental and safety regulations.
27

The following table summarizes ongoing and expansion capital expenditures:

| Six Months Ended June 30, 2023
Capital expenditures in Accounts payable at December 31, 2022 | $ | 14,879 |
Purchases of property, plant and equipment | 38,847 |
Less: Capital expenditures in Accounts payable at June 30, 2023 | (9,832) |
Cash paid for capital expenditures | $ | 43,894 |

For 2023, we expect our total capital expenditures to be approximately $110 million to $120 million compared to $89 million in 2022, reflecting increased spend due to critical infrastructure, other maintenance, and growth and cost savings projects. Capital expenditures are deployed for various ongoing investments and initiatives to improve reliability, yield and quality, expand production capacity and comply with HSE regulations.
Critical Accounting Policies and Estimates
The preparation of our Condensed Consolidated Financial Statements in accordance with U.S. GAAP is based on the selection and application of accounting policies that require us to make significant estimates and assumptions about the effects of matters that are inherently uncertain. We consider these accounting policies to be critical to the understanding of our Condensed Consolidated Financial Statements. For a full description of our critical accounting policies, refer to Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our 2022 Form 10-K. While there have been no material changes to our critical accounting policies, or the methodologies or assumptions we apply under them, we continue to monitor such methodologies and assumptions.
Recent Accounting Pronouncements
See “Note 2. Recent Accounting Pronouncements” to the Condensed Consolidated Financial Statements included in Part I. Item 1 of this Form 10-Q.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest Rate Risk
Our exposure to risk based on changes in interest rates during the six-month period ended June 30, 2023 relates primarily to the Revolving Credit Facility. The Revolving Credit Facility bears interest at floating rates. For variable rate debt, interest rate changes generally do not affect the fair market value of such debt assuming all other factors remain constant but do impact future earnings and cash flows. Accordingly, we may be exposed to interest rate risk on borrowings under the Credit Agreement.
Based on current borrowing levels at June 30, 2023, a 25-basis point fluctuation in interest rates for the six months ended June 30, 2023 would have resulted in an increase or decrease to our interest expense of approximately $0.4 million.
See “Note 12. Derivative and Hedging Instruments” to the Condensed Consolidated Financial Statements, included in Part I. Item 1 of this Form 10-Q, for a discussion relating to credit and market, commodity price and interest rate risk.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
The Company maintains disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports filed or submitted under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.
Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Because there are inherent limitations in all control systems, no
28

evaluation of controls can provide absolute assurance that all control issues and instances of fraud have been, or will be, detected.
Our Chief Executive Officer and Chief Financial Officer, with the assistance of other members of our management, conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report. Based upon such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective at a reasonable assurance level as of June 30, 2023, the end of the period covered by this quarterly report.
Changes in Internal Control over Financial Reporting
Management has not identified any change in the Company's internal control over financial reporting that occurred during the quarter ended June 30, 2023 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
The Philadelphia Air Management Services (“PAMS”) notified the Company in November 2021 of certain alleged violations involving emission control equipment at the Company’s manufacturing facility in Philadelphia, Pennsylvania, which in each case were self-reported by the Company and subsequently corrected. The Company discussed this matter with PAMS and responded to various information requests. In April 2023, the Company and PAMS agreed to a settlement, pursuant to which the Company paid a civil penalty of approximately $62 thousand.
The United States Environmental Protection Agency (“EPA”) and the Company entered into an Administrative Compliance Order on Consent in February 2023 in connection with alleged violations involving the Company’s risk management program at its manufacturing facility in Hopewell, Virginia. The Company is currently implementing an EPA-approved work plan to improve its risk management program at Hopewell. The Company also has entered into discussions with the EPA regarding an Administrative Compliance Order in connection with alleged violations involving the Company’s stormwater and other discharges. These EPA allegations may potentially subject the Company to penalties. Although the outcome of the matter cannot be predicted with certainty, we do not believe that it will have a material adverse effect on our consolidated financial position, results of operations or operating cash flows.
From time to time, we are involved in litigation relating to claims arising outside of the ordinary course of our business operations. We are not a party to, and, to our knowledge, there are no pending claims or actions against us, the ultimate disposition of which could be expected to have a material adverse effect on our consolidated financial position, results of operations or operating cash flows.
ITEM 1A. RISK FACTORS
There have been no material changes to our risk factors as previously disclosed in Item 1A of Part I of the Company’s 2022 Form 10-K, which are hereby incorporated by reference.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
On May 4, 2018, the Company announced that the Board authorized a share repurchase program of up to $75 million of the Company’s common stock. On February 22, 2019, the Company announced that the Board authorized a share repurchase program of up to an additional $75 million of the Company's common stock, which was in addition to the remaining capacity authorized under the May 2018 share repurchase program. On February 17, 2023, the Company announced that the Board authorized a share repurchase program of up to an additional $75 million of the Company's common stock, which was in addition to the remaining capacity available under the previously approved share repurchase program. Repurchases may be made from time to time on the open market in accordance with Rule 10b-18 of the Exchange Act, including through the use of trading plans intended to qualify under Rule 10b5-1 of the Exchange Act. The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The repurchase program has no expiration date and may be modified, suspended or discontinued at any time.
29

The below table sets forth the repurchases of Company common stock, by month, for the quarter ended June 30, 2023. During the quarter ended June 30, 2023, 402,951 shares were purchased under our share repurchase program an d 7,911 share s were withheld to cover tax withholding obligations in connection with the vesting of equity awards.
ISSUER PURCHASES OF EQUITY SECURITIES

Period |  | Total Number of Shares Purchased |  | Average Price Paid per Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plan |  | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plan
April 2023 | (1) | 105,573 |  |  | $ | 38.94 |  |  | 105,028 |  |  | $ | 96,097,492 |
May 2023 |  | 153,075 |  |  | 35.25 |  |  | 153,075 |  |  | 90,701,265 |
June 2023 | (2) | 152,214 |  |  | 35.01 |  |  | 144,848 |  |  | 85,626,238 |
Total |  | 410,862 |  |  | $ | 36.11 |  |  | 402,951 |  |  |

(1) Total number of shares purchased includes 545 shares covering tax withholding obligations in connection with the vesting of equity awards
(2) Total number of shares purchased includes 7,366 shares covering tax withholding obligations in connection with the vesting of equity awards
During the period July 1, 2023 through July 28, 2023, we repurchased an additional 94,715 shares at a weighted average market price of $36.45 per share primarily under the currently authorized repurchase program.
ITEM 5. OTHER INFORMATION
Insider Rule 10b5-1 Trading Plans
During the quarter ended June 30, 2023, none of our directors or executive officers adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K.
30

ITEM 6. EXHIBITS

Exhibit |  | Description
3.1 |  | Amended and Restated Certificate of Incorporation of AdvanSix Inc. (conformed copy) (incorporated by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q filed on August 1, 2019).
3.2 |  | Amended and Restated By-laws of AdvanSix Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on June 20, 20 23).
10.1 |  | First Amendment to Credit Agreement, dated as of June 27, 2023, among AdvanSix Inc., the lenders party thereto and Truist Bank, as administrative agent (with annexed Amended and Restated Credit Agreement)
31.1 |  | Rule 13a-14(a)/15d-14(a) Certification of the Company’s Principal Executive Officer.
31.2 |  | Rule 13a-14(a)/15d-14(a) Certification of the Company’s Principal Financial Officer.
32.1 |  | Section 1350 Certification of the Company’s Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the SEC nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
32.2 |  | Section 1350 Certification of the Company’s Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the SEC nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
101.INS |  | Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
101.SCH |  | Inline XBRL Taxonomy Extension Schema Document
101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 |  | Cover Page Interactive Data File (formatted as Inline XBRL and included in Exhibit 101)

† Indicates management contract or compensatory plan.
31

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| ADVANSIX INC.
Date: August 4, 2023 | By: |  | /s/ Michael Preston
|  |  | Michael Preston
|  |  | Senior Vice President and Chief Financial Officer

32